Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 730-747

  Guzman Aranguez, A ^a   Loma, P ^a   Pintor, J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

age related macular degeneration; corneal neovascularization; diabetic retinopathy; eye; glaucoma; retinitis pigmentosa; siRNAs; therapy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AGN 211745; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BEVASIRANIB; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; COCHLIN; MITOMYCIN; OMEGA 3 FATTY ACID; OSTEONECTIN; PEGAPTANIB; PF 655; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROTEIN BAX; PROTEIN C JUN; PURINERGIC P2Y2 RECEPTOR; RANIBIZUMAB; RETINOL; RETINOL PALMITATE; SMALL INTERFERING RNA; SYL 040012; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; XANTHOPHYLL;

ANIMAL EXPERIMENT; CARDIOVASCULAR DISEASE; CONJUNCTIVAL HYPEREMIA; CORNEA NEOVASCULARIZATION; DEGRADATION; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; EYE COLOR; EYE DISEASE; EYELASH; GENE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TRANSFER; GLAUCOMA; HUMAN; LASER COAGULATION; LONG TERM CARE; NONHUMAN; OCULAR FIBROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERIN GENE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; RNA INTERFERENCE; RTP801 GENE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

AGE-RELATED MACULAR DEGENERATION; CORNEAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; EYE; GLAUCOMA; RETINITIS PIGMENTOSA; SIRNAS; THERAPY;

ANIMALS; EYE DISEASES; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84885113592     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12330     Document Type: Review

References (172)

1. Ahmed Z, Kalinski H, Berry M, Almasieh M, Ashush H, Slager N, et al. (2011). Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis 2: e173.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC) 5th edition. Br J Pharmacol 164: S1-S324.
3. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
4. Alm A, Nilsson SF, (2009). Uveoscleral outflow-a review. Exp Eye Res 88: 760-768.
5. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. (2006). Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55: 2401-2411.
6. Antonetti DA, Klein R, Gardner TW, (2012). Diabetic retinopathy. N Engl J Med 366: 1227-1239.
7. Ashikari M, Tokoro M, Itaya M, Nozaki M, Ogura Y, (2010). Suppression of laser-induced choroidal neovascularization by nontargeted siRNA. Invest Ophthalmol Vis Sci 51: 3820-3824.
8. Bachmann B, Taylor RS, Cursiefen C, (2010). Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 117: 1300-1305.e7.
9. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC, et al. (2010). Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 128: 403-411.
10. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Willett WC, (2012). Omega-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 130: 707-711.
11. Beverly M, Hartsough K, Machemer L, Pavco P, Lockridge J, (2006). Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex. J Chromatogr B Analyt Technol Biomed Life Sci 835: 62-70.
12. Bhattacharya SK, Rockwood EJ, Smith SD, Bonilha VL, Crabb JS, Kuchtey RW, et al. (2005). Proteomics reveal Cochlin deposits associated with glaucomatous trabecular meshwork. J Biol Chem 280: 6080-6084.
13. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. (2006). 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3: 199-204.
14. Brafman A, Mett I, Shafir M, Gottlieb H, Damari G, Gozlan-Kelner S, et al. (2004). Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 45: 3796-3805.
15. Brar VS, Sharma RK, Murthy RK, Chalam KV, (2010). Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis 16: 1848-1853.
16. Brigstock DR, (2003). The CCN family: a new stimulus package. J Endocrinol 178: 169-175.
17. Brucker A, (2006). Small interfering RNA (CAND5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration. Retina society. Combined Retina Society/Gonin Society Meeting.
18. Buller C, Johnson D, (1994). Segmental variability of the trabecular meshwork in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 35: 3841-3851.
19. Campa C, Harding SP, (2011). Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12: 173-181.
20. Cashman SM, Binkley EA, Kumar-Singh R, (2005). Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Ther 12: 1223-1228.
21. Castany M, Jordi I, Catala J, Gual A, Morales M, Gasull X, et al. (2011). Glaucoma patients present increased levels of diadenosine tetraphosphate, Ap(4)A, in the aqueous humour. Exp Eye Res 92: 221-226.
22. Chang JH, Gabison EE, Kato T, Azar DT, (2001a). Corneal neovascularization. Curr Opin Ophthalmol 12: 242-249.
23. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT, (2012). Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 57: 415-429.
24. Chang L, Crowston JG, Sabin CA, Khaw PT, Akbar AN, (2001b). Human tenon's fibroblast-produced ifnbeta and the prevention of t-cell apoptosis. Invest Ophthalmol Vis Sci 42: 1531-1538.
25. Chen P, Yin H, Wang Y, Xie L, (2012). Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1alpha in a mouse model of closed eye contact lens wear. Mol Vis 18: 864-873.
26. Cheung N, Mitchell P, Wong TY, (2010). Diabetic retinopathy. Lancet 376: 124-136.
27. Chiu YL, Rana TM, (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9: 1034-1048.
28. Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, et al. (2009). Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A 106: 7137-7142.
29. Chopdar A, Chakravarthy U, Verma D, (2003). Age related macular degeneration. BMJ 326: 485-488.
30. ClinicalTrials (2008). Safety and efficacy study evaluating the combination of bevasiranib and Lucentis therapy in wet AMD (COBALT).
31. Comes N, Borras T, (2007). Functional delivery of synthetic naked siRNA to the human trabecular meshwork in perfused organ cultures. Mol Vis 13: 1363-1374.
32. Congdon NG, Friedman DS, Lietman T, (2003). Important causes of visual impairment in the world today. JAMA 290: 2057-2060.
33. Costagliola C, Agnifili L, Arcidiacono B, Duse S, Fasanella V, Mastropasqua R, et al. (2012). Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 12: 1299-1313.
34. Crooke A, Mediero A, Guzman-Aranguez A, Pintor J, (2009). Silencing of P2Y2 receptor delays Ap4A-corneal re-epithelialization process. Mol Vis 15: 1169-1178.
35. da Cruz L, Coley BF, Dorn J, Merlini F, Filley E, Christopher P, et al. (2013). The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol 97: 632-636.
36. Deshpande MC, Davies MC, Garnett MC, Williams PM, Armitage D, Bailey L, et al. (2004). The effect of poly(ethylene glycol) molecular architecture on cellular interaction and uptake of DNA complexes. J Control Release 97: 143-156.
37. Devi TS, Lee I, Huttemann M, Kumar A, Nantwi KD, Singh LP, (2012). TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal Muller glia under chronic hyperglycemia: implications for diabetic retinopathy. Exp Diabetes Res 2012: 438238.
38. Dursun A, Arici MK, Dursun F, Ozec AV, Toker MI, Erdogan H, et al. (2012). Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. Int J Ophthalmol 5: 448-451.
39. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T, (2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
40. Elbashir SM, Lendeckel W, Tuschl T, (2001b). RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200.
41. Emerson MV, Lauer AK, (2008). Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2: 377-388.
42. Evans T, Deng DX, Chen S, Chakrabarti S, (2000). Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 49: 662-666.
43. Fan S, Hejkal JJ, Gulati V, Galata S, Camras CB, Toris CB, (2011). Aqueous humor dynamics during the day and night in volunteers with ocular hypertension. Arch Ophthalmol 129: 1162-1166.
44. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, et al. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA 12: 1188-1196.
45. Feinstein HA, Kleinman ME, Nozaki M, Kalinski H, Mett I, Ambati J, et al. (2009). PF-04523655 (REDD14), an siRNA compound targeting RTP801, penetrates retinal cells producing target gene knockdown and avoiding TLR3 activation. Invest Ophthalmol Vis Sci (ARVO Meeting Abstracts) 50: 5693.
46. Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, Rait J, et al. (1999). Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet 8: 899-905.
47. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC, (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
48. de Fougerolles AR, (2008). Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19: 125-132.
49. Gaglione M, Messere A, (2010). Recent progress in chemically modified siRNAs. Mini Rev Med Chem 10: 578-595.
50. Gastinger MJ, Singh RS, Barber AJ, (2006). Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 47: 3143-3150.
51. Goel M, Sienkiewicz AE, Picciani R, Wang J, Lee RK, Bhattacharya SK, (2012). Cochlin, intraocular pressure regulation and mechanosensing. PLoS One 7: e34309.
52. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS, (2007). Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res 47: 1202-1208.
53. Gu L, Chen H, Tuo J, Gao X, Chen L, (2010). Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA. Exp Eye Res 91: 433-439.
54. Guo H, Gao J, Wu X, (2012). Toll-like receptor 2 siRNA suppresses corneal inflammation and attenuates Aspergillus fumigatus keratitis in rats. Immunol Cell Biol 90: 352-357.
55. Guo J, Fisher KA, Darcy R, Cryan JF, O'Driscoll C, (2010). Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst 6: 1143-1161.
56. Gupta D, Illingworth C, (2011). Treatments for corneal neovascularization: a review. Cornea 30: 927-938.
57. Guzman-Aranguez A, Colligris B, Pintor J, (2013). Contact lenses: promising devices for ocular drug delivery. J Ocul Pharmacol Ther 29: 189-199.
58. Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA, (2004). RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 32: 5991-6000.
59. Hartong DT, Berson EL, Dryja TP, (2006). Retinitis pigmentosa. Lancet 368: 1795-1809.
60. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. (2002). Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279.
61. Hernan I, Gamundi MJ, Planas E, Borras E, Maseras M, Carballo M, (2011). Cellular expression and siRNA-mediated interference of rhodopsin cis-acting splicing mutants associated with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 52: 3723-3729.
62. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270.
63. Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, et al. (2012). Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology 119: 779-788.
64. Iacono P, Battaglia Parodi M, Bandello F, (2010). Antivascular endothelial growth factor in diabetic retinopathy. Dev Ophthalmol 46: 39-53.
65. Jampel HD, McGuigan LJ, Dunkelberger GR, L'Hernault NL, Quigley HA, (1988). Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol 106: 89-94.
66. Jiang J, Xia XB, Xu HZ, Xiong Y, Song WT, Xiong SQ, et al. (2009). Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol 218: 66-74.
67. Johnson EC, Guo Y, Cepurna WO, Morrison JC, (2009). Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp Eye Res 88: 808-815.
68. Johnson LN, Cashman SM, Kumar-Singh R, (2008). Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther 16: 107-114.
69. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I, (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462.
70. Judge AD, Bola G, Lee AC, MacLachlan I, (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505.
71. Junglas B, Yu AH, Welge-Lussen U, Tamm ER, Fuchshofer R, (2009). Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp Eye Res 88: 1065-1075.
72. Junglas B, Kuespert S, Seleem AA, Struller T, Ullmann S, Bosl M, et al. (2012). Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am J Pathol 180: 2386-2403.
73. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, et al. (2010). RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 150: 33-39.e2.
74. Kalloniatis M, Fletcher EL, (2004). Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options. Clin Exp Optom 87: 65-80.
75. Kariko K, Buckstein M, Ni H, Weissman D, (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175.
76. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. (2002). The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713; discussion 829-730.
77. Kern TS, (2007). Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007 (95103): 1-14.
78. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH, (2001). Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 15: 2654-2659.
79. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, et al. (2005). Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 12: 555-561.
80. Kiel JW, Hollingsworth M, Rao R, Chen M, Reitsamer HA, (2011). Ciliary blood flow and aqueous humor production. Prog Retin Eye Res 30: 1-17.
81. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY, et al. (2004). Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165: 2177-2185.
82. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597.
83. Kleinman ME, Kaneko H, Cho WG, Dridi S, Fowler BJ, Blandford AD, et al. (2012). Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther 20: 101-108.
84. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M, (2012). Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122: 4213-4217.
85. Kurz D, Ciulla TA, (2002). Novel approaches for retinal drug delivery. Ophthalmol Clin North Am 15: 405-410.
86. Lingor P, Koeberle P, Kugler S, Bahr M, (2005). Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain 128 (Pt 3): 550-558.
87. Liu H, Yang R, Tinner B, Choudhry A, Schutze N, Chaqour B, (2008). Cysteine-rich protein 61 and connective tissue growth factor induce deadhesion and anoikis of retinal pericytes. Endocrinology 149: 1666-1677.
88. Liu JH, Kripke DF, Hoffman RE, Twa MD, Loving RT, Rex KM, et al. (1998). Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci 39: 2707-2712.
89. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, et al. (1999). Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 40: 2912-2917.
90. Liu JH, Kripke DF, Weinreb RN, (2004). Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 138: 389-395.
91. Liu Q, Wu K, Qiu X, Yang Y, Lin X, Yu M, (2012). siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice. Curr Mol Med 12: 1015-1027.
92. Ma JB, Ye K, Patel DJ, (2004). Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429: 318-322.
93. Macknight AD, McLaughlin CW, Peart D, Purves RD, Carre DA, Civan MM, (2000). Formation of the aqueous humor. Clin Exp Pharmacol Physiol 27: 100-106.
94. Mao H, Gorbatyuk MS, Rossmiller B, Hauswirth WW, Lewin AS, (2012). Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther 23: 356-366.
95. Markovskaya A, Crooke A, Guzman-Aranguez AI, Peral A, Ziganshin AU, Pintor J, (2008). Hypotensive effect of UDP on intraocular pressure in rabbits. Eur J Pharmacol 579: 93-97.
96. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R, et al. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 24: 559-565.
97. Martin-Gil A, de Lara MJ, Crooke A, Santano C, Peral A, Pintor J, (2012). Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits. Br J Pharmacol 165: 1163-1172.
98. Massof RW, Fishman GA, (2010). How strong is the evidence that nutritional supplements slow the progression of retinitis pigmentosa? Arch Ophthalmol 128: 493-495.
99. Mediero A, Alarma-Estrany P, Pintor J, (2009). New treatments for ocular hypertension. Auton Neurosci 147: 14-19.
100. Mezentsev A, Mastyugin V, Seta F, Ashkar S, Kemp R, Reddy DS, et al. (2005). Transfection of cytochrome P4504B1 into the cornea increases angiogenic activity of the limbal vessels. J Pharmacol Exp Ther 315: 42-50.
101. Mincione F, Scozzafava A, Supuran CT, (2008). The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 14: 649-654.
102. Morris MB, Dastmalchi S, Church WB, (2009). Rhodopsin: structure, signal transduction and oligomerisation. Int J Biochem Cell Biol 41: 721-724.
103. Moses RA, (1981). Intraocular pressure. In:, Moses RA, (ed.). Adler's Physiology of the Eye: Clinical Application. C.V. Mosby Co: St Louis, pp. 227-254.
104. Myles ME, Neumann DM, Hill JM, (2005). Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 57: 2063-2079.
105. Nakamura H, Siddiqui SS, Shen X, Malik AB, Pulido JS, Kumar NM, et al. (2004). RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 10: 703-711.
106. Nathanson JA, (1981). Human ciliary process adrenergic receptor: pharmacological characterization. Invest Ophthalmol Vis Sci 21: 798-804.
107. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, et al. (2012a). Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS Study). Invest Ophthalmol Vis Sci 53: 7666-7674.
108. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, et al. (2012b). Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 26: 1099-1105.
109. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, et al. (2012c). Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 119: 1867-1873.
110. Nozaki RB, Mett I, Notkin N, Papismadov I, Shalom L, Takeda A, et al. (2006). RTP801i: a novel anti-angiogenic strategy superior to and cooperative with VEGF-A blockade in suppressing CNV. Invest Ophthalmol Vis Sci (ARVO Meeting Abstracts) 47: 900.
111. O'Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T, et al. (2007). RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 81: 127-135.
112. Orban TI, Izaurralde E, (2005). Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 11: 459-469.
113. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, et al. (2005). Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 19: 963-965.
114. Oshitari T, Polewski P, Chadda M, Li AF, Sato T, Roy S, (2006). Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes 55: 86-92.
115. Palfi A, Ader M, Kiang AS, Millington-Ward S, Clark G, O'Reilly M, et al. (2006). RNAi-based suppression and replacement of rds-peripherin in retinal organotypic culture. Hum Mutat 27: 260-268.
116. Pañeda C, Martinez T, Gonzalez V, Ruz V, Jimenez AI, (2013). Development of SYL040012, a siRNA for treating increased intraocular pressure associated to glaucoma. AOPT 2013 Scientific Meeting 1: 96.
117. Parker JS, Roe SM, Barford D, (2005). Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature 434: 663-666.
118. Peeters L, Sanders NN, Braeckmans K, Boussery K, Van de Voorde J, De Smedt SC, et al. (2005). Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci 46: 3553-3561.
119. Peeters L, Sanders NN, Demeester J, De Smedt SC, (2007). Challenges in non-viral ocular gene transfer. Biochem Soc Trans 35 (Pt 1): 47-49.
120. Peral A, Gallar J, Pintor J, (2009). Adenine nucleotide effect on intraocular pressure: involvement of the parasympathetic nervous system. Exp Eye Res 89: 63-70.
121. Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP, (2009). Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221: 262-272.
122. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP, (2010). Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis 1: e65.
123. Petrs-Silva H, Yasumura D, Matthes MT, LaVail MM, Lewin AS, Hauswirth WW, (2012). Suppression of rds expression by siRNA and gene replacement strategies for gene therapy using rAAV vector. Adv Exp Med Biol 723: 215-223.
124. Phelan JK, Bok D, (2000). A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. Mol Vis 6: 116-124.
125. Pintor J, (2011). Silencing Beta2-Adrenergic Receptors reduces intraocular pressure: a new approach for glaucoma therapy. An R Acad Nac Farm 78: 230-240.
126. Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, et al. (2011). Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117: 5541-5550.
127. Pitkanen L, Ruponen M, Nieminen J, Urtti A, (2003). Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res 20: 576-583.
128. Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, et al. (2012). Nanoparticle-mediated delivery of shRNA. VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 53: 2837-2844.
129. Quigley HA, (2011). Glaucoma. Lancet 377: 1367-1377.
130. Rand TA, Ginalski K, Grishin NV, Wang X, (2004). Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci U S A 101: 14385-14389.
131. Rand TA, Petersen S, Du F, Wang X, (2005). Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123: 621-629.
132. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, et al. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9: 210-216.
133. Riley MV, Kishida K, (1986). ATPases of ciliary epithelium: cellular and subcellular distribution and probable role in secretion of aqueous humor. Exp Eye Res 42: 559-568.
134. Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS, (2012). Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech 5: 444-456.
135. Roy S, Sato T, Paryani G, Kao R, (2003). Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 52: 1229-1234.
136. Roy S, Nasser S, Yee M, Graves DT, (2011). A long-term siRNA strategy regulates fibronectin overexpression and improves vascular lesions in retinas of diabetic rats. Mol Vis 17: 3166-3174.
137. Saika S, Yamanaka O, Baba Y, Kawashima Y, Shirai K, Miyamoto T, et al. (2001). Accumulation of latent transforming growth factor-beta binding protein-1 and TGF beta 1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol 239: 234-241.
138. Sbai O, Devi TS, Melone MA, Feron F, Khrestchatisky M, Singh LP, et al. (2010). RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. J Cell Sci 123 (Pt 24): 4332-4339.
139. Seet LF, Su R, Toh LZ, Wong TT, (2012). In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin C. J Cell Mol Med 16: 1245-1259.
140. Seigel D, Richoz O, (2013). Omega-3 Intake in patients with retinitis pigmentosa receiving vitamin A. JAMA Ophthalmol 131: 267-268.
141. Seta F, Patil K, Bellner L, Mezentsev A, Kemp R, Dunn MW, et al. (2007). Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat 84: 116-127.
142. van Setten G, Berglin L, Blalock TD, Schultz G, (2005). Detection of connective tissue growth factor in subretinal Fluid following retinal detachment: possible contribution to subretinal scar formation, preliminary results. Ophthalmic Res 37: 289-292.
143. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al. (2006). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13: 225-234.
144. Shi F, Wasungu L, Nomden A, Stuart MC, Polushkin E, Engberts JB, et al. (2002). Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem J 366 (Pt 1): 333-341.
145. Silver LH, (1998). Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 126: 400-408.
146. Singh N, Higgins E, Amin S, Jani P, Richter E, Patel A, et al. (2007). Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea 26: 65-72.
147. Sioud M, (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348: 1079-1090.
148. Sohn S, Hur W, Joe MK, Kim JH, Lee ZW, Ha KS, et al. (2002). Expression of wild-type and truncated myocilins in trabecular meshwork cells: their subcellular localizations and cytotoxicities. Invest Ophthalmol Vis Sci 43: 3680-3685.
149. Song LY, Ahkong QF, Rong Q, Wang Z, Ansell S, Hope MJ, et al. (2002). Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 1558: 1-13.
150. Su Y, Yang CY, Li Z, Xu F, Zhang L, Wang F, et al. (2012). Smad7 siRNA inhibit expression of extracellular matrix in trabecular meshwork cells treated with TGF-beta2. Mol Vis 18: 1881-1884.
151. Tamm ER, (2009). The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res 88: 648-655.
152. Tessitore A, Parisi F, Denti MA, Allocca M, Di Vicino U, Domenici L, et al. (2006). Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model. Mol Ther 14: 692-699.
153. The AGIS Investigators (2000). The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429-440.
154. Tian B, Geiger B, Epstein DL, Kaufman PL, (2000). Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci 41: 619-623.
155. Tolentino MJ, Brucker AJ, Fosnot J, Ying GS, Wu IH, Malik G, et al. (2004). Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24: 660.
156. Toris CB, Camras CB, Yablonski ME, (1999). Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 128: 8-14.
157. Tosi J, Sancho-Pelluz J, Davis RJ, Hsu CW, Wolpert KV, Sengillo JD, et al. (2011). Lentivirus-mediated expression of cDNA and shRNA slows degeneration in retinitis pigmentosa. Exp Biol Med (Maywood) 236: 1211-1217.
158. Tovar-Vidales T, Clark AF, Wordinger RJ, (2011). Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells. Exp Eye Res 93: 442-451.
159. Tshionyi M, Shay E, Lunde E, Lin A, Han KY, Jain S, et al. (2012). Hemangiogenesis and lymphangiogenesis in corneal pathology. Cornea 31: 74-80.
160. Turchinovich A, Zoidl G, Dermietzel R, (2010). Non-viral siRNA delivery into the mouse retina in vivo. BMC Ophthalmol 10: 25.
161. Verrecchia F, Mauviel A, (2002). Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118: 211-215.
162. Weinreb RN, Khaw PT, (2004). Primary open-angle glaucoma. Lancet 363: 1711-1720.
163. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL, (2002). Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 47 (Suppl. 1): S53-S64.
164. Winkler JL, Kedees MH, Guz Y, Teitelman G, (2012). Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy. Mol Vis 18: 874-886.
165. Wistrand PJ, Stjernschantz J, Olsson K, (1997). The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 41 (Suppl. 2): S129-S138.
166. Yang H, Huang Y, Chen X, Liu J, Lu Y, Bu L, et al. (2010a). The role of CTGF in the diabetic rat retina and its relationship with VEGF and TGF-beta(2), elucidated by treatment with CTGFsiRNA. Acta Ophthalmol 88: 652-659.
167. Yang HW, Chen XL, Liu ZL, Liu J, Bu LM, (2010b). CTGFsiRNA ameliorates retinal cells apoptosis in streptozotocin-induced diabetic rats. Int J Ophthalmol 3: 120-124.
168. Ye H, Qian Y, Lin M, Duan Y, Sun X, Zhuo Y, et al. (2010). Cationic nano-copolymers mediated IKKbeta targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery. Mol Vis 16: 2502-2510.
169. Yuan C, Zins EJ, Clark AF, Huang AJ, (2007). Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro. Mol Vis 13: 2083-2095.
170. Zhang K, Zhang L, Weinreb RN, (2012). Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 11: 541-559.
171. Zhang X, Li A, Ge J, Reigada D, Laties AM, Mitchell CH, (2007). Acute increase of intraocular pressure releases ATP into the anterior chamber. Exp Eye Res 85: 637-643.
172. Zuo L, Fan Y, Wang F, Gu Q, Xu X, (2010). A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization. Curr Eye Res 35: 375-384.